This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals in the U.S.
In this module, Dr. Somers guides clinicians through translating a positive OSA screen into the correct diagnostic testing pathway. Participants will learn to confidently select home sleep apnea testing (HSAT) for uncomplicated adult cases, while identifying the critical cardiopulmonary, neurological, or comorbidity red flags that strictly necessitate in-lab polysomnography (PSG) or specialist referral.
Session Highlights
- Apply evidence-based decision algorithms to identify uncomplicated adult patients with a high pre-test probability of moderate-to-severe OSA who are appropriate candidates for home sleep apnea testing (HSAT).
- Recognize clinical "red flags"—such as significant cardiorespiratory disease, suspected central sleep apnea, chronic opioid use, or a history of stroke—that necessitate referral for in-lab polysomnography (PSG) or specialist evaluation.
Prefer to watch in Spanish? Click Here.
Who Should Participate?
This program is designed for healthcare professionals who seek to incorporate structured OSA screening and diagnostic activation into routine cardiometabolic management workflows.
- Primary Care Physicians and Family Medicine Practitioners
- Nurse Practitioners
- Physician Assistants
This is Module Two of Six, See Modules 1, 3, 4 5 and 6 Here.
Prefer to read? See our Key Clinical Summary Here.
Faculty
Dr Virend Somers
Dr Virend Somers is a Professor of Medicine and Consultant in Preventive Cardiology at Mayo Clinic, and a leading expert in sleep apnea and its cardiovascular consequences. His research focuses on the physiological mechanisms linking obstructive sleep apnea with cardiovascular disease, including changes in autonomic and vascular function, blood pressure, and heart failure. Through his work directing Mayo Clinic’s Sleep Facility, Dr Somers has contributed significantly to understanding how disordered sleep affects cardiovascular health, with a focus on translating these insights into improved recognition, management, and care for patients with sleep apnea.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr Virend Somers, faculty for this educational activity, has the following relevant financial relationships: Consultant Apnimed, GEM Med, Jazz Pharmaceuticals, Lilly.
The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associate Continuing Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information
There is no fee for this educational activity.
This continuing education activity is active starting September 11th 2026, and will expire on July 1st 2028.